The transaction will create a vertically integrated platform and cardiovascular disease franchise, which will support the discovery and development of cardiovascular drugs
Valo Health acquires TARA Biosystems. (Credit: Robina Weermeijer on Unsplash)
Health technology company Valo Health has acquired TARA Biosystems to create a vertically integrated platform for the discovery and development of cardiovascular drugs.
TARA Biosystems is a biotechnology company that leverages advanced stem cell biology and tissue engineering to generate a versatile biology platform, in-vitro.
It has developed a platform to capture integrated physiologic endpoints of human cardiac function across a wide range of cardiac disease phenotypes.
With the acquisition, TARA’s unique human 3D tissue engineering and cardiac disease modelling capabilities will be added to Valo’s AI-backed Opal Computational Platform.
The transaction will create a vertically integrated platform and cardiovascular disease franchise, which supports cardiovascular drugs discovery and development.
TARA founder and CEO Misti Ushio said: “TARA’s proprietary human cardiac disease platform enables Valo to advance the discovery of new medicines for cardiovascular disease, ushering in a new era for patients.
“TARA joining the Valo family is a natural extension of our pre-existing business relationship and is a unique fit given our shared vision of leveraging machine learning and human-centric data to transform the treatment of cardiovascular diseases.”
Valo is a technology company focused on transforming the drug discovery and development process using human-centric data and AI computation.
The acquisition of TARA builds on the company’s extensive cardiovascular platform, which already includes deep clinical human cardiovascular disease data.
It has designed the Opal Computational Platform to have an integrated set of capabilities that help transform data into valuable insights, said Valo Health.
With the platform, Valo is enabled to advance its pipeline across cardiovascular metabolic renal, oncology, and neurodegenerative disease.
Valo founder and CEO David Berry said: “This acquisition builds on Valo’s unyielding commitment to identify new treatments for cardiovascular disease, creating a best-in-class end-to-end drug discovery and development platform aimed at accelerating the delivery of lifesaving drugs to the millions of patients suffering from cardiovascular diseases.”